Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

'Intelligent' cancer drug development boosts success rates

A new era of intelligent cancer drug development has spurred a leap in the proportion of drugs reaching patients, according to a study by Cancer Research UK scientists published in Nature Reviews Drug Discovery.

17 Nov 2008

U.S. patents granted to Virginia Tech for targets and methods to develop new drugs for malaria

Virginia Tech Intellectual Properties (VTIP) announces that the US Patent and Trademark Office has granted a patent for targets and methods to develop new drugs for malaria.

11 Nov 2008

All stem cells are not created equal, explains expert

During the course of the Presidential campaign, Obama signaled his intention to reverse Bush's controversial limit on federal funding of embryonic stem cell research.

11 Nov 2008

Discovery of mechanism that regulates the development of stem cells into neurons

Researchers at the University of Southern California (USC) have identified a novel mechanism in the regulation and differentiation of neural stem cells.

11 Nov 2008

10 years of stem cells science

Ten years ago this month (Nov. 6, 1998), the publication in the journal Science of a short paper entitled "Embryonic Stem Cell Lines Derived from Human Blastocysts" rocked biology - and the world - as the all-purpose stem cell and its possibilities were ushered into the limelight.

7 Nov 2008

A virus-infecting virus

Using the Genome Sequencer System from 454 Life Sciences, a Roche company, French scientists have identified a small virus that can actually be parasitic to a larger one.

7 Nov 2008

Scientists identify compounds for stem-cell production from adult cells

In the study, the scientists screened known drugs and identified small molecules that could replace conventional reprogramming genes, which can have dangerous side effects.

6 Nov 2008

Tibotec presents interim findings for TMC435, investigational hepatitis C treatment

New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.

4 Nov 2008

GSK to acquire Genelabs Technologies

GlaxoSmithKline and Genelabs Technologies, Inc announced today that they have entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (pounds Sterling 35 million) through a tender offer of $1.30 per share in cash. This strategic acquisition will strengthen GSK's effort to develop and deliver novel therapies against the hepatitis C virus (HCV).

29 Oct 2008

Researchers find new chemical key that could unlock hundreds of new antibiotics

Chemistry researchers at The University of Warwick and the John Innes Centre, have found a novel signalling molecule that could be a key that will open up hundreds of new antibiotics unlocking them from the DNA of the Streptomyces family of bacteria.

29 Oct 2008

Griffith University and Pfizer in new partnership to unlock nature's cure for infections

In the quest to develop the next generation of anti-infective medicine, Griffith University and Pfizer, the world's largest research-based pharmaceutical company, announced a leading partnership today.

27 Oct 2008

New drugs the next casualty of the credit crunch

Scientists at an international conference have been warned that the next casualty of the credit crunch could be new drugs.

27 Oct 2008

'Lab-on-Bead' to speed drug discovery

Researchers at Wake Forest University are using nanotechnology to search for new cancer-fighting drugs through a process that could be up to 10,000 times faster than current methods.

6 Oct 2008

Cancer Research UK and Astex Therapeutics join forces to develop new anti-cancer treatment

Cancer Research UK, Cancer Research Technology (CRT) - the charity's development and commercialisation arm - and Astex Therapeutics Limited announced today that they have agreed to take into development a potential new anti-cancer treatment.

30 Sep 2008

Existing anti-obesity drugs may be effective against flu, hepatitis and HIV

Viruses dramatically increase cellular metabolism, and existing anti-obesity drugs may represent a new way to block these metabolic changes and inhibit viral infection, according to a study published today in the journal Nature Biotechnology.

29 Sep 2008

CytRx to present new data on molecular chaperone drug discovery technology

CytRx Corporation today announced that Bin Zhang, Ph.D., Associate Director of Biochemistry and Screening, will present at the monthly meeting of the San Diego "LEADS" discussion group, the premium San Diego consortium of screening researchers, to be held on October 1, 2008.

25 Sep 2008

New technology to analyse human cells

A new technology which enables scientists to identify proteins by making a map of the energy flow inside the protein is revealed in Proceedings of the National Academy of Sciences (PNAS) journal.

23 Sep 2008

S*BIO initiates trials of oral JAK2 inhibitor for hematological malignancies

S*BIO Pte Ltd today announced the initiation of multi-center Phase I clinical trials of SB1518, a potent and orally-active JAK2 inhibitor, in patients with leukemia and certain types of lymphoma.

17 Sep 2008

Geron issued U.S. patent for cardiomyocytes from human embryonic stem cells

Geron Corporation has announced the issuance of U.S. Patent No. 7,425,448, with broad claims to cardiomyocytes derived from human embryonic stem cells (hESCs). The patent runs until at least April 2025 (subject to any patent term extension that may be available). Geron's GRNCM1 program is developing hESC-derived cardiomyocytes for the treatment of heart disease.

16 Sep 2008

Domainex has core intellectual property rights granted for Europe

Domainex Ltd (Domainex), an innovative biopharmaceutical company, today announced the grant of European Patent No.1442134 for its Combinatorial Domain Hunting (CDH) Technology.

From Domainex 14 Sep 2008